1231929-97-7|1231930-82|LY2835219, also called abemaciclib, is also a selective CDK4/CDK6 inhibitor, blocking cells at G1 phase due to the inhibition of the phosphorylation of pRb protein. Abemaciclib has been developed by Eli Lilly and is in phase I clinical trials for treating non-small-cell lung carcinoma. LY2835219 already demonstrated very good results for patients suffering from breast cancer and a phase I trial in combination with hormone therapies for breast cancer will finish in 2016 . A phase III study of LY2835219 combined with fulvestrant for women with HER2-negative metastatic breast cancer is planned in 2014.
Copyright © 2014-2015 Tubepharm. All Rights Reserved.
Tel：+86 021 5433 8626 Fax：+86 021 5433 8626*801 E-mail: email@example.com
All of our products, unless clearly indicated otherwise, are sold for research or manufacturing purposes only, are not for human, veterinary and household use.
The products under valid patent protection are not offered at this time. It is fully client's responsibility to comply with the rules, regulations and patent laws.